实施轮状病毒普遍大规模接种后急性胃肠炎住院情况
爱沙尼亚于2014年7月实施轮状病毒普遍大规模接种(RV UMV),本研究比较接种前(2007-2013)与接种后(2015-2018)轮状病毒流行季急性胃肠炎(AGE)住院变化,并比较2015与2016连续两个流行季0-18岁AGE住院患者特征;接种后AGE住院率从10/1000降至8/1000(RR 0.81,95%CI 0.79-0.83),<1岁和1-4岁轮状病毒胃肠炎(RVGE)住院分别减少81%(95%CI 77-84)和55%(95%CI 52-58),诺如病毒胃肠炎(NoVGE)住院增加(RR 1.8,95%CI 1.6-1.9),RVGE患者中位年龄从2岁增至3岁(p<0.01),2015 vs 2016重症比例82.5% vs 70.5%。
要点
- 接种后AGE住院率从10/1000降至8/1000(RR 0.81,95%CI 0.79-0.83)。
- <1岁和1-4岁RVGE住院分别减少81%(95%CI 77-84)和55%(95%CI 52-58)。
- NoVGE住院增加(RR 1.8,95%CI 1.6-1.9),RVGE患者中位年龄从2岁增至3岁(p<0.01)。
核心结论
- RV UMV使<4岁儿童RVGE住院立即且持续减少,总体AGE住院减少并伴随住院患儿严重程度下降。
研究设计与样本
- 使用爱沙尼亚健康保险基金(HIF)数据库描述疫苗接种前后AGE住院模式。
- 2015年2月1日至2016年8月30日在七家爱沙尼亚医院开展为期两年的观察性多中心研究,评估符合预定AGE标准的全部患者特征。
- 多中心观察性研究共纳入2249例AGE住院患者,年龄0-18岁。
主要发现
- 接种后AGE住院率从10/1000降至8/1000(RR 0.81,95%CI 0.79-0.83)。
- <1岁和1-4岁RVGE住院分别减少81%(95%CI 77-84)和55%(95%CI 52-58)。
- NoVGE住院增加(RR 1.8,95%CI 1.6-1.9)。
- RVGE患者中位年龄从2岁增至3岁(p<0.01),RVGE、NoVGE和其他GE患者住院时长在连续两个流行季均缩短。
- 按Vesikari临床严重度评分系统,两个RV季节严重度评分分布有统计学显著变化(p<0.001),趋势为AGE住院严重度降低;2015 vs 2016重症比例82.5% vs 70.5%。
关键数值与推荐
- AGE住院率:接种后8/1000 vs 接种前10/1000(RR 0.81,95%CI 0.79-0.83)。
- RVGE住院减少:<1岁81%(95%CI 77-84),1-4岁55%(95%CI 52-58)。
- NoVGE住院:RR 1.8(95%CI 1.6-1.9)。
- RVGE患者中位年龄:2016年3岁 vs 2015年2岁(p<0.01)。
- 重症比例:2016年70.5% vs 2015年82.5%(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Estonia implemented rotavirus universal mass vaccination (RV UMV) in July 2014. We aimed to describe changes in acute gastroenteritis (AGE) hospitalization during RV seasons before (2007-2013) and after (2015-2018) RV UMV and compare patient profile of hospitalized AGE patients aged 0-18 years during first two consecutive RV seasons 2015 vs 2016. METHODS: We described AGE hospitalization patterns pre-and post-vaccine era using Estonian Health Insurance Fund (HIF) database. During a two-year observational multicenter study in seven Estonian hospitals from 01st of February 2015 to 30th August 2016 we assessed patient profile of all patients who met pre-determined AGE criteria. RESULTS: In post-vaccine era AGE hospitalization rate decreased from 10 to 8 per 1000 population (RR 0.81, 95% CI 0.79-0.83) compared to pre-vaccine era. Decreased RV seasonal activity, 81% (95% CI 77-84) and 55% (95% CI 52-58) reduction of rotavirus gastroenteritis (RVGE) hospitalization among age groups <1 and 1-4, respectively and upsurge of norovirus gastroenteritis (NoVGE) hospitalizations (RR = 1.8; 95% CI 1.6-1.9) was seen. In the multicenter observational study, among 2249 AGE patients hospitalized median age of RVGE patients increased from 2 to 3 years (p < 0.01) and duration of hospital stay decreased among RVGE, NoVGE and other GE patients during two consecutive RV seasons. According to Vesikari Clinical Severity Scoring System statistically significant change of severity score distribution in two RV seasons was seen (p < 0.001) with trend towards less severe AGE hospitalizations; 82.5% vs 70.5% severe cases in 2015 vs 2016, respectively. CONCLUSION: RV UMV lead to immediate and sustainable reduction of hospitalizations due to RVGE in children aged <4 years and reduction of overall AGE accompanied with the decrease in the severity of hospitalized children.
引用
- Kõivumägi K, Toompere K, Soeorg H, et al. Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus. Vaccine. 2020. PMID: 32067818. doi:10.1016/j.vaccine.2020.01.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。